1
|
Wiesinger AM, Bigger B, Giugliani R, Scarpa M, Moser T, Lampe C, Kampmann C, Lagler FB. The Inflammation in the Cytopathology of Patients With Mucopolysaccharidoses- Immunomodulatory Drugs as an Approach to Therapy. Front Pharmacol 2022; 13:863667. [PMID: 35645812 PMCID: PMC9136158 DOI: 10.3389/fphar.2022.863667] [Citation(s) in RCA: 10] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2022] [Accepted: 04/27/2022] [Indexed: 01/31/2023] Open
Abstract
Mucopolysaccharidoses (MPS) are a group of lysosomal storage diseases (LSDs), characterized by the accumulation of glycosaminoglycans (GAGs). GAG storage-induced inflammatory processes are a driver of cytopathology in MPS and pharmacological immunomodulation can bring improvements in brain, cartilage and bone pathology in rodent models. This manuscript reviews current knowledge with regard to inflammation in MPS patients and provides hypotheses for the therapeutic use of immunomodulators in MPS. Thus, we aim to set the foundation for a rational repurposing of the discussed molecules to minimize the clinical unmet needs still remaining despite enzyme replacement therapy (ERT) and hematopoietic stem cell transplantation (HSCT).
Collapse
Affiliation(s)
- Anna-Maria Wiesinger
- Institute of Congenital Metabolic Diseases, Paracelsus Medical University, Salzburg, Austria
- European Reference Network for Hereditary Metabolic Diseases, MetabERN, Udine, Italy
- *Correspondence: Anna-Maria Wiesinger,
| | - Brian Bigger
- European Reference Network for Hereditary Metabolic Diseases, MetabERN, Udine, Italy
- Stem Cell and Neurotherapies, Division of Cell Matrix Biology and Regenerative Medicine, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, United Kingdom
| | - Roberto Giugliani
- Department of Genetics, Medical Genetics Service and Biodiscovery Laboratory, HCPA, UFRGS, Porto Alegre, Brazil
| | - Maurizio Scarpa
- European Reference Network for Hereditary Metabolic Diseases, MetabERN, Udine, Italy
- Regional Coordinating Center for Rare Diseases, University Hospital Udine, Udine, Italy
| | - Tobias Moser
- Department of Neurology, Christian Doppler University Hospital, Paracelsus Medical University, Salzburg, Austria
| | - Christina Lampe
- European Reference Network for Hereditary Metabolic Diseases, MetabERN, Udine, Italy
- Department of Child and Adolescent Medicine, Center of Rare Diseases, University Hospitals Giessen/Marburg, Giessen, Germany
| | - Christoph Kampmann
- Department of Pediatric Cardiology, University Hospital Mainz, Mainz, Germany
| | - Florian B. Lagler
- Institute of Congenital Metabolic Diseases, Paracelsus Medical University, Salzburg, Austria
- European Reference Network for Hereditary Metabolic Diseases, MetabERN, Udine, Italy
| |
Collapse
|
2
|
Oxidative Stress in Mucopolysaccharidoses: Pharmacological Implications. Molecules 2021; 26:molecules26185616. [PMID: 34577086 PMCID: PMC8468662 DOI: 10.3390/molecules26185616] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/21/2021] [Revised: 09/11/2021] [Accepted: 09/14/2021] [Indexed: 12/26/2022] Open
Abstract
Although mucopolysaccharidoses (MPS) are caused by mutations in genes coding for enzymes responsible for degradation of glycosaminoglycans, storage of these compounds is crucial but is not the only pathomechanism of these severe, inherited metabolic diseases. Among various factors and processes influencing the course of MPS, oxidative stress appears to be a major one. Oxidative imbalance, occurring in MPS and resulting in increased levels of reactive oxidative species, causes damage of various biomolecules, leading to worsening of symptoms, especially in the central nervous system (but not restricted to this system). A few therapeutic options are available for some types of MPS, including enzyme replacement therapy and hematopoietic stem cell transplantation, however, none of them are fully effective in reducing all symptoms. A possibility that molecules with antioxidative activities might be useful accompanying drugs, administered together with other therapies, is discussed in light of the potential efficacy of MPS treatment.
Collapse
|
3
|
Montero R, Yubero D, Salgado MC, González MJ, Campistol J, O'Callaghan MDM, Pineda M, Delgadillo V, Maynou J, Fernandez G, Montoya J, Ruiz-Pesini E, Meavilla S, Neergheen V, García-Cazorla A, Navas P, Hargreaves I, Artuch R. Plasma coenzyme Q 10 status is impaired in selected genetic conditions. Sci Rep 2019; 9:793. [PMID: 30692599 PMCID: PMC6349877 DOI: 10.1038/s41598-018-37542-2] [Citation(s) in RCA: 25] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2018] [Accepted: 12/04/2018] [Indexed: 12/19/2022] Open
Abstract
Identifying diseases displaying chronic low plasma Coenzyme Q10 (CoQ) values may be important to prevent possible cardiovascular dysfunction. The aim of this study was to retrospectively evaluate plasma CoQ concentrations in a large cohort of pediatric and young adult patients. We evaluated plasma CoQ values in 597 individuals (age range 1 month to 43 years, average 11 years), studied during the period 2005–2016. Patients were classified into 6 different groups: control group of healthy participants, phenylketonuric patients (PKU), patients with mucopolysaccharidoses (MPS), patients with other inborn errors of metabolism (IEM), patients with neurogenetic diseases, and individuals with neurological diseases with no genetic diagnosis. Plasma total CoQ was measured by reverse-phase high-performance liquid chromatography with electrochemical detection and ultraviolet detection at 275 nm. ANOVA with Bonferroni correction showed that plasma CoQ values were significantly lower in the PKU and MPS groups than in controls and neurological patients. The IEM group showed intermediate values that were not significantly different from those of the controls. In PKU patients, the Chi-Square test showed a significant association between having low plasma CoQ values and being classic PKU patients. The percentage of neurogenetic and other neurological patients with low CoQ values was low (below 8%). In conclusión, plasma CoQ monitoring in selected groups of patients with different IEM (especially in PKU and MPS patients, but also in IEM under protein-restricted diets) seems advisable to prevent the possibility of a chronic blood CoQ suboptimal status in such groups of patients.
Collapse
Affiliation(s)
- Raquel Montero
- Inborn errors of metabolism Unit, Institut de Recerca Sant Joan de Déu, Barcelona, Spain.,CIBER de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III Spain, Madrid, Spain
| | - Delia Yubero
- Inborn errors of metabolism Unit, Institut de Recerca Sant Joan de Déu, Barcelona, Spain
| | - Maria C Salgado
- Inborn errors of metabolism Unit, Institut de Recerca Sant Joan de Déu, Barcelona, Spain
| | - María Julieta González
- Inborn errors of metabolism Unit, Institut de Recerca Sant Joan de Déu, Barcelona, Spain
| | - Jaume Campistol
- Inborn errors of metabolism Unit, Institut de Recerca Sant Joan de Déu, Barcelona, Spain.,CIBER de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III Spain, Madrid, Spain
| | - Maria Del Mar O'Callaghan
- Inborn errors of metabolism Unit, Institut de Recerca Sant Joan de Déu, Barcelona, Spain.,CIBER de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III Spain, Madrid, Spain
| | - Mercè Pineda
- Inborn errors of metabolism Unit, Institut de Recerca Sant Joan de Déu, Barcelona, Spain
| | - Verónica Delgadillo
- Inborn errors of metabolism Unit, Institut de Recerca Sant Joan de Déu, Barcelona, Spain
| | - Joan Maynou
- Department of Genetic and Molecular Medicine, Institut de Recerca Sant Joan de Déu, Barcelona, Spain
| | - Guerau Fernandez
- Department of Genetic and Molecular Medicine, Institut de Recerca Sant Joan de Déu, Barcelona, Spain
| | - Julio Montoya
- CIBER de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III Spain, Madrid, Spain.,Departamento de Bioquimica y Biologia Molecular y Celular, Universidad Zaragoza-Instituto de Investigación Sanitaria de Aragón (IISAragon), Zaragoza, Spain
| | - Eduardo Ruiz-Pesini
- CIBER de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III Spain, Madrid, Spain.,Departamento de Bioquimica y Biologia Molecular y Celular, Universidad Zaragoza-Instituto de Investigación Sanitaria de Aragón (IISAragon), Zaragoza, Spain
| | - Silvia Meavilla
- Inborn errors of metabolism Unit, Institut de Recerca Sant Joan de Déu, Barcelona, Spain
| | - Viruna Neergheen
- Neurometabolic Unit, National Hospital, Queen Square, London, UK
| | - Angels García-Cazorla
- Inborn errors of metabolism Unit, Institut de Recerca Sant Joan de Déu, Barcelona, Spain.,CIBER de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III Spain, Madrid, Spain
| | - Placido Navas
- CIBER de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III Spain, Madrid, Spain.,Centro Andaluz de Biología del Desarrollo, Universidad Pablo de Olavide, Sevilla, Spain
| | - Iain Hargreaves
- Neurometabolic Unit, National Hospital, Queen Square, London, UK.,School of Pharmacy, Liverpool John Moores University, Liverpool, UK
| | - Rafael Artuch
- Inborn errors of metabolism Unit, Institut de Recerca Sant Joan de Déu, Barcelona, Spain. .,CIBER de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III Spain, Madrid, Spain.
| |
Collapse
|
4
|
Yubero D, Montero R, Martín MA, Montoya J, Ribes A, Grazina M, Trevisson E, Rodriguez-Aguilera JC, Hargreaves IP, Salviati L, Navas P, Artuch R, Jou C, Jimenez-Mallebrera C, Nascimento A, Pérez-Dueñas B, Ortez C, Ramos F, Colomer J, O’Callaghan M, Pineda M, García-Cazorla A, Espinós C, Ruiz A, Macaya A, Marcé-Grau A, Garcia-Villoria J, Arias A, Emperador S, Ruiz-Pesini E, Lopez-Gallardo E, Neergheen V, Simões M, Diogo L, Blázquez A, González-Quintana A, Delmiro A, Domínguez-González C, Arenas J, García-Silva MT, Martín E, Quijada P, Hernández-Laín A, Morán M, Rivas Infante E, Ávila Polo R, Paradas Lópe C, Bautista Lorite J, Martínez Fernández EM, Cortés AB, Sánchez-Cuesta A, Cascajo MV, Alcázar M, Brea-Calvo G. Secondary coenzyme Q 10 deficiencies in oxidative phosphorylation (OXPHOS) and non-OXPHOS disorders. Mitochondrion 2016; 30:51-8. [DOI: 10.1016/j.mito.2016.06.007] [Citation(s) in RCA: 61] [Impact Index Per Article: 7.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/10/2016] [Revised: 05/06/2016] [Accepted: 06/29/2016] [Indexed: 11/30/2022]
|